ALMS vs RARE · rev $3.4M vs rev $350.0M
Alumis Inc. Common Stock (ALMS) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Alumis Inc. Common Stock (ALMS) is a biotechnology company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported ALMS revenue for 2026-06-30 was $3.4M. Net income was -$235.3M. Revenue was up 95.5% from 2026-03-31 to 2026-06-30. ALMS currently screens at market cap $311.6M.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
ALMS currently screens at market cap $311.6M. RARE currently screens at market cap $2.79B.
Not investment advice. Open the ALMS and RARE stock pages for the full models.
Not investment advice.